gray market retatrutide Today, we shared new data from two Phase 3 trials of retatrutide, our investigational triple agonist. Learn more at our link in bio PEPTIDE SOURCES & SAFETY •,

Rare but serious side effects, such as pancreatitis or gallbladder problems, can occur, so careful screening and ongoing monitoring are essential

Solutions & Gaps Existing solutions are built on top of established business models including DTC prescriptions, meal delivery kits, and telehealth Late-stage/public companies in telehealth and meal delivery capitalized on GLP-1 offerings with a range of supplemental products or offerings for GLP-1 users

SURMOUNT-1 enrolled 2,539 adults with a mean baseline BMI of 38.0, and 94.5% of participants had a BMI of 30 or higher

Proprietary data sets on adherence patterns, novel coaching methodologies, or predictive side-effect management can all serve as defensible IP

Those who experience significant benefit may need to consider long-term use to maintain it